World
AstraZeneca chemotherapy gets US nod for certain type of endometrial cancer
Endometrial cancer was responsible for nearly 12,000 fatalities in the US in 2022. (Representative Image)
AstraZeneca has said its blockbuster cancer drug Imfinzi combined with chemotherapy has been approved by the US as treatment for adult patients with primary, advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).
The approval from the US Food and Drug Administration came after a late stage trial showed that Imfinzi along with chemotherapy drugs carboplatin and paclitaxel, then followed by Imfinzi by itself, reduced the risk of disease progression or death by 58% in specific endometrial cancer patients, compared to chemotherapy alone, the Anglo-Swedish drugmaker said on Monday.
“Immunotherapy in combination with chemotherapy is emerging as a new standard of care in this setting, and the approval of Imfinzi offers an important new option for patients with mismatch repair deficient disease,” Dave Fredrickson, executive vice-president of the company’s oncology business unit, said in a statement.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
First Published: Jun 17 2024 | 1:18 PM IST
U.S. soldier wounded during Gaza pier mission dies months after being injured
North Korea launches short-range ballistic missile hours before US election
Russia behind plot to plant bombs on cargo planes, Western official says
Is The US Election Really So Close?
North Korea fires a barrage of ballistic missiles toward the sea ahead of US election
What If The US Election Ends In A Trump-Kamala Harris Tie?
‘He’s realizing that he could lose’: the Trump campaign is panicking
Election updates and polls: Harris, Trump make final push in Pennsylvania
We May Not Know The Results Of 2024 US Elections On November 5. Here’s Why
